Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 446, 15 (1 March 2007) | doi:10.1038/446015a; Published online 28 February 2007
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
- More Challenges
- Powered by:
nature jobs
Medical Writer
- Cactus Global
- Mumbai 400053 India
Faculty Positions in Immunology
- Harvard Medical School (HMS), Dana-Farber Cancer Institute (DFCI)
- Boston, MA
A merger too far?
Abstract
Bristol-Myers Squibb has been stoking its research productivity. Meredith Wadman investigates whether an acquisition would be the right prescription for the company.
Last month, the drug industry was abuzz with reports that Sanofi-Aventis was set to buy up Bristol-Myers Squibb. The move would make Paris-based Sanofi the world's second-largest drug maker, after Pfizer.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
ASCPT NewsClinical Pharmacology & Therapeutics News and Views
News and ViewsClinical Pharmacology & Therapeutics News and Views
